Hybridan

Our passion is raising growth capital for exciting, fast growth companies that want to take their business to the next level. We raise capital for companies both listed and unlisted in the most efficient manner possible and pride ourselves as being one of the few consistently profitable broking firms in the City. This has been achieved through a highly disciplined approach when seeking to create both corporate and institutional relationships.

Your Partner for Growth

Your Partner for Growth, Hybridan

Equity Bottom-Up

<ul><li>A further two contracts worth a combined £111,000 were announced this morning by the Company, as the total revenue pipeline continues to build.</li><li>These contracts with a new UK-based biopharmaceutical client have been won by the recently established Biometrics services division.</li><li>The Physiomics team have delivered over 100 commercial projects for drug development clients, including but not limited to, Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics and Cancer Research UK.</li></ul>

A further two contracts worth a combined £111,000 were announced this morning by the Company, as the total revenue pipeline continues to build.These contracts with a new UK-based biopharmaceutical client have been won by the recently established Biometrics services division.The Physiomics team have delivered over 100 commercial projects for drug development clients, including but not limited to, Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics and Cancer Research UK.

Hybridan Research: Physiomics plc: Synergistic Services